PODD Insulet Corporation

  1. Stocks
  2. Healthcare
  3. NASDAQ: PODD

Price (delayed)

$148.16

Market cap

$10.28B

P/E Ratio

27.69

Dividend/share

N/A

EPS

$5.35

Enterprise value

$10.69B

?
Relative Growth: Rel. Growth: 99
Relative Strength: Rel. Strength: 8
Relative Valuation: Rel. Valuation: 61
Relative Profitability: Rel. Profitability: 93

Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin ...

Highlights
PODD's price to earnings (P/E) is 99% lower than its 5-year quarterly average of 2103.6 and 55% lower than its last 4 quarters average of 61.6
PODD's net income has surged by 59% year-on-year and by 24% since the previous quarter
The equity is up by 9% QoQ but it is down by 2.8% YoY
Insulet's quick ratio has decreased by 2.6% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.insulet.com
Peers: ICUI DCTH TNDM DXCM

Key stats

What are the main financial stats of PODD

PODD stock price

How has the Insulet stock price performed over time
Intraday
0.88%
1 week
3.36%
1 month
-9.5%
1 year
-54.81%
YTD
-47.88%
QTD
-2.69%

Financial performance

How have Insulet's revenue and profit performed over time
Revenue
$3.05B
Gross profit
$2.17B
Operating income
$515.8M
Net income
$375.3M
Gross margin
71.1%
Net margin
12.3%
PODD's net income has surged by 59% year-on-year and by 24% since the previous quarter
PODD's gross profit is up by 30% YoY and by 5% from the previous quarter
PODD's revenue is up by 29% year-on-year and by 5% since the previous quarter
Insulet's operating income has increased by 27% YoY

Price vs fundamentals

How does PODD's price correlate with its fundamentals

Growth

What is Insulet's growth rate over time

Valuation

What is Insulet stock price valuation
PODD P/E details
P/E
27.69
P/B
7.22
P/S
3.36
EV/EBIT
19.32
EV/EBITDA
16.38
EV/Sales
3.5
PODD's price to earnings (P/E) is 99% lower than its 5-year quarterly average of 2103.6 and 55% lower than its last 4 quarters average of 61.6
The EPS has soared by 59% YoY and by 24% from the previous quarter
PODD's price to book (P/B) is 70% less than its 5-year quarterly average of 24.2 and 39% less than its last 4 quarters average of 11.9
The equity is up by 9% QoQ but it is down by 2.8% YoY
PODD's price to sales (P/S) is 68% lower than its 5-year quarterly average of 10.6 and 45% lower than its last 4 quarters average of 6.1
PODD's revenue is up by 29% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is Insulet business performance
Insulet's return on invested capital has surged by 93% YoY and by 17% QoQ
The return on assets has surged by 68% year-on-year and by 26% since the previous quarter
PODD's ROE is up by 45% YoY and by 25% QoQ
The ROS has grown by 33% YoY and by 12% from the previous quarter

Dividends

What is PODD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PODD.

Financial health

How did Insulet financials performed over time
The total assets is 82% higher than the total liabilities
The company's total liabilities fell by 13% YoY but it rose by 3.5% QoQ
The current ratio has increased by 10% YoY
The company's debt is 33% lower than its equity
The company's debt fell by 32% YoY
The debt to equity has decreased by 30% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.